Mr. Rashid Bux reports

BIOMARK SECURES BROAD U.S. PATENT FOR URINE-BASED LUNG CANCER SCREENING, EXPANDING DIFFERENTIATED LIQUID BIOPSY TESTING PLATFORM

The U.S. Patent and Trademark Office has issued a notice of patent allowance for application No. 18/304,741, titled "Method of Detecting Lung Cancer." The allowed patent covers the proprietary use of urine to detect lung cancer, assess treatment response, screen at-risk populations, and evaluate drug efficacy using a highly specific panel of polyamine metabolites and other critical analytes.

Disrupting the genomic status quo: cancer as a metabolic disease

Biomark's pioneer work in clinical mass spectrometry and metabolomic profiling for early cancer detection proves that the company's proprietary panel of polyamine biomarkers is not locked to a single matrix. By focusing on the metabolic signatures, Biomark's platform identifies the very first biochemical changes a tumour undergoes. This allows for detection significantly earlier than traditional ctDNA tests, which must wait for a tumour cell to die and shed fragmented DNA into the bloodstream. This newly allowed patent marks a massive strategic evolution, accelerating the company's expansion from blood-based testing into non-invasive alternative biological fluids. Urine provides meaningful strategic optionality to offer diagnostic tests beyond blood-based matrices alone, particularly for early-stage and screening applications.

With lung cancer claiming the single largest market share of the global liquid biopsy market at 32.1 per cent of a market projected to reach over $24-billion (U.S.) by 2035, a non-invasive, highly scalable MS-based urine test offers an incredibly lucrative alternative to expensive sequencing workflows. The allowed patent covers five distinct clinical and commercial applications: detection and diagnosis of lung cancer; staging; non-invasive population screening; assessment of treatment response; and evaluation of drug or therapeutic efficacy in clinical development.

"Receiving this notice of patent allowance from the USPTO underscores the unmatched versatility of our underlying science," said Rashid Ahmed Bux, chief executive officer and founder of Biomark Diagnostics. "The market has been heavily focused on first-generation genomic screening funded around blood-based DNA fragmentation, methylation or circulating tumour DNA, but we invested early in mass spectrometry and metabolomics because we knew the technology was deep and multidimensional. While the company's core platform has been validated in blood through rigorous clinical studies, expanding to urine introduces an entirely new biological matrix with profound diagnostic depth."

About Biomark Diagnostics Inc.

Biomark is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.